Pfizer Inc (PFIZ34) Fair Value & Analysis
Healthcare · BR · Market cap R$772B
Fair value as of: Jun 24, 2026
From 25 valuation models · updated 11 days ago
Fair value updated Jun 24, 2026 — revised from R$5.22 to R$5.94 (+13.8%) since Jun 23, 2026. Share price −2.1% over the past month.
Price vs Fair Value (12 months)
12‑month range R$31.20 – R$37.13 · fair‑value band R$4.16 – R$7.73 · the R$32.07 price screens above the R$5.94 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Pfizer Inc (PFIZ34) currently trades at R$32.07, while our model-based Fair Value estimate is R$5.94 — implying the stock looks roughly 81.5% overvalued today. We read business quality at 60/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Pfizer Inc generated revenue of R$63.3B at a net margin of 11.8%. Revenue grew 5.4% year over year. It earns a return on equity of 8.3%. Net debt stands at R$62.8B. Fundamentals as of Jun 24, 2026
Our scenario range runs from R$4.16 (bear case) to R$7.73 (bull case); at R$32.07, the current price sits above that range. The share trades about 13% below its 52-week high and 6% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -42% fair-value upside — at -81%, PFIZ34 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Pfizer Inc reported revenue of R$62.6B in FY2025 versus R$81.3B in FY2021, a compound −6.3%/yr. Reported net income was R$7.8B in FY2025, compounding −22.9%/yr from FY2021.
Is PFIZ34 fairly valued? → Check now
Recent news
- Is Pfizer Inc. (PFE) A Good Stock To Buy Now?
- Edison Scientific and Population Health Partners Partner to Build the Next Generation of Biotech Companies
- China surpassing Europe in Drug Innovation and Development, Pfizer Inc. (PFE) Executive says
- Pfizer (PFE) Dismissed From Generic Drug Price Fixing Lawsuit
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,102 | $395.92 | -64% |
| Johnson & Johnson, JNJ | 4,128 MXN | 159.68 MXN | -96% |
| AbbVie Inc ABBV | $230.01 | $133.86 | -42% |
| Roche Holding ROGN | 7,050 MXN | 6,743 MXN | -4% |
| Merck & Co MRCK34 | R$77.92 | R$40.37 | -48% |
| AstraZeneca PLC A1ZN34 | R$154.95 | R$23.54 | -85% |
| Novartis AG N1VS34 | R$78.65 | R$12.63 | -84% |
| Novo Nordisk A/S, NOVOB | kr 283.10 | kr 404.89 | +43% |
| Amgen Inc AMGN | 6,170 MXN | 4,893 MXN | -21% |
| Gilead Sciences, Inc GIS | €115.42 | €71.19 | -38% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Pfizer Inc (PFIZ34) undervalued?
What is the fair value of PFIZ34?
What is the quality score of PFIZ34?
What is the revenue of Pfizer Inc (PFIZ34)?
What is the net profit margin of PFIZ34?
Does Pfizer Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.